NCT04174196View on ClinicalTrials.gov

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 19, 2019

Primary Completion Date

November 19, 2025

Study Completion Date

November 19, 2025

Conditions
PlasmacytomaPlasmacytoma of BoneMultiple Myeloma
Interventions
DRUG

CC-486

Participants will be treated with CC-486 and lenalidomide for 6 cycles

DRUG

Lenalidomide

Participants will be treated with CC-486 and lenalidomide for 6 cycles

RADIATION

Radiation Therapy

Radiation therapy will be initiated to the plasmacytoma after cycle 2

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04174196 - A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | Biotech Hunter | Biotech Hunter